MediPal Holdings Corporation (MAHLY) Stock Price & Analysis
MediPal Holdings Corporation (MAHLY) — price $20.20 (0.00%), as of the Nov 19, 2026 trading session; market cap $4.13B.
Educational signal · not a buy or sell recommendation · How to read this
MediPal Holdings Corporation · MAHLY
MediPal Holdings Corporation, based in Tokyo, specializes in the wholesale distribution of pharmaceuticals and healthcare products across Japan.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $20.20 | |
| Change on the day | 0.00% | |
| 52-week range | $15.37 – $20.35 | |
| Market capitalisation | $4.13B | — |
| Price / earnings (trailing) | 15.29 | |
| Shares traded on the day | 200 |
Price & events
Other perspectives
Council score for MediPal Holdings (MAHLY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is MediPal Holdings (MAHLY), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MediPal Holdings Corporation (MAHLY) is the company analyzed here. It employs 13,024 people and is led by Kuniaki Imagawa. In Q2 FY2027 it reported revenue of ¥979.43B and net income of ¥9.37B. The market values it at $4.13B.
What do the latest results show for MediPal Holdings (MAHLY)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ¥979.43B.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ¥979.43B | ¥9.37B | ¥46.15 (diluted) |
| Q1 FY2027 | ¥1002.53B | ¥13.83B | ¥67.81 (diluted) |
| Q4 FY2026 | ¥922.33B | ¥5.21B | ¥25.56 (diluted) |
| Q3 FY2026 | ¥1032.41B | ¥15.60B | ¥76.03 (diluted) |
What are the financial strengths and risks for MediPal Holdings (MAHLY)?
Short answer · as of
The distress and quality screens read Altman Z 2.81 · Piotroski F 5. Trailing ratios: ROE 6.8% · ROA 2.2% · current ratio 1.08 · earnings yield 6.5% · free-cash-flow yield 1.7%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MAHLY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MAHLY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about MediPal Holdings (MAHLY)?
What Investors Ask About MediPal Holdings (MAHLY)
These answers are editorial: 1 of these 8 answers is drawn from the MAHLY research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is MAHLY a good stock to buy?
Stock Expert AI does not rate MAHLY buy, sell or hold. MediPal Holdings Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MAHLY stock price today?
The last price recorded for MediPal Holdings Corporation (MAHLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for MAHLY?
MediPal Holdings Corporation faces several risks, including potential regulatory changes that could impact its operations in the pharmaceutical distribution landscape.
What are the key factors to evaluate for MAHLY?
Evaluate MAHLY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. With Japan's increasing focus on rare diseases, MediPal's strategic initiatives in this area could enhance its revenue streams and market presence over the next five years. Not financial advice.
How frequently does MAHLY data refresh on this page?
MAHLY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MAHLY's recent stock price performance?
MediPal Holdings Corporation (MAHLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio encompassing pharmaceuticals, medical supplies, and healthcare services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MAHLY overvalued or undervalued right now?
The trailing P/E of MediPal Holdings Corporation (MAHLY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MAHLY before investing?
Before investing in MediPal Holdings Corporation (MAHLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com